CN102417540A - 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用 - Google Patents

一种聚乙二醇修饰的整合素阻断剂hm-3及其应用 Download PDF

Info

Publication number
CN102417540A
CN102417540A CN2011103705299A CN201110370529A CN102417540A CN 102417540 A CN102417540 A CN 102417540A CN 2011103705299 A CN2011103705299 A CN 2011103705299A CN 201110370529 A CN201110370529 A CN 201110370529A CN 102417540 A CN102417540 A CN 102417540A
Authority
CN
China
Prior art keywords
tumor
human
group
gly
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011103705299A
Other languages
English (en)
Chinese (zh)
Inventor
徐寒梅
常海民
康志安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Pharmaceutical University
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Priority to CN2011103705299A priority Critical patent/CN102417540A/zh
Publication of CN102417540A publication Critical patent/CN102417540A/zh
Priority to AU2012343020A priority patent/AU2012343020B2/en
Priority to EP12851929.5A priority patent/EP2784093B1/en
Priority to KR1020147016557A priority patent/KR20140096373A/ko
Priority to US14/359,462 priority patent/US20140329759A1/en
Priority to PCT/CN2012/084788 priority patent/WO2013075600A1/zh
Priority to IN4482CHN2014 priority patent/IN2014CN04482A/en
Priority to KR1020197020874A priority patent/KR102106485B1/ko
Priority to US15/332,539 priority patent/US20170100489A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/04—Peptides being immobilised on, or in, an organic carrier entrapped within the carrier, e.g. gel, hollow fibre
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2011103705299A 2011-11-21 2011-11-21 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用 Pending CN102417540A (zh)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CN2011103705299A CN102417540A (zh) 2011-11-21 2011-11-21 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
AU2012343020A AU2012343020B2 (en) 2011-11-21 2012-11-17 Polyethylene glycol-modified integrin blocker HM-3 and use thereof
EP12851929.5A EP2784093B1 (en) 2011-11-21 2012-11-17 Polyethylene glycol-modified integrin blocker hm-3 and use thereof
KR1020147016557A KR20140096373A (ko) 2011-11-21 2012-11-17 폴리에틸렌글리콜이 수식된 인테그린 차단제 hm-3 및 그 응용
US14/359,462 US20140329759A1 (en) 2011-11-21 2012-11-17 Polyethylene glycol-modified integrin blocker hm-3 and use thereof
PCT/CN2012/084788 WO2013075600A1 (zh) 2011-11-21 2012-11-17 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
IN4482CHN2014 IN2014CN04482A (https=) 2011-11-21 2012-11-17
KR1020197020874A KR102106485B1 (ko) 2011-11-21 2012-11-17 폴리에틸렌글리콜이 수식된 인테그린 차단제 hm-3 및 그 응용
US15/332,539 US20170100489A1 (en) 2011-11-21 2016-10-24 Polyethylene glycol-modified integrin blocker hm-3 and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011103705299A CN102417540A (zh) 2011-11-21 2011-11-21 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用

Publications (1)

Publication Number Publication Date
CN102417540A true CN102417540A (zh) 2012-04-18

Family

ID=45942198

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011103705299A Pending CN102417540A (zh) 2011-11-21 2011-11-21 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用

Country Status (7)

Country Link
US (2) US20140329759A1 (https=)
EP (1) EP2784093B1 (https=)
KR (2) KR20140096373A (https=)
CN (1) CN102417540A (https=)
AU (1) AU2012343020B2 (https=)
IN (1) IN2014CN04482A (https=)
WO (1) WO2013075600A1 (https=)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075600A1 (zh) * 2011-11-21 2013-05-30 Xu Hanmei 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
CN103623394A (zh) * 2013-12-11 2014-03-12 南京安吉生物科技有限公司 一种peg-hm-3和铂类、紫杉醇类或他滨类药物在制备实体瘤药物中的用途
CN103656615A (zh) * 2013-12-11 2014-03-26 南京安吉生物科技有限公司 一种hm-3和铂类、紫杉醇类或他滨类药物在制备实体瘤药物中的用途
CN103720667A (zh) * 2014-01-09 2014-04-16 中国药科大学 Ap-25多肽冻干粉针制剂及其制备方法和用途
CN103739673A (zh) * 2013-12-31 2014-04-23 罗瑞雪 一种聚乙二醇修饰的抑制白介素-6多肽及其应用
CN103739671A (zh) * 2013-12-31 2014-04-23 罗瑞雪 一种聚乙二醇修饰的抑制核因子－κB多肽及其应用
CN103739669A (zh) * 2013-12-31 2014-04-23 罗瑞雪 一种抑制白介素-6多肽及其应用
CN103736078A (zh) * 2014-01-09 2014-04-23 南京安吉生物科技有限公司 mPEG-HM-3多肽冻干粉针制剂及其制备方法和用途
CN103819542A (zh) * 2014-02-28 2014-05-28 中国药科大学 一种聚乙二醇修饰及蛋白质融合表达的整合素阻断剂ap-25及其应用
CN104127378A (zh) * 2014-08-11 2014-11-05 中国药科大学 mPEG-SC20K-HM-3多肽注射液及其制备方法和用途
CN105622721A (zh) * 2015-12-16 2016-06-01 李斯文 一种聚乙二醇修饰的血管生成抑制剂hs-1及其应用
CN105646667A (zh) * 2016-04-06 2016-06-08 南京安吉生物科技有限公司 聚乙二醇修饰的血管生成抑制剂hm-1及其应用
CN107857800A (zh) * 2017-11-09 2018-03-30 北京赛升药业股份有限公司 一种长效整合素抑制剂及其应用
CN108623693A (zh) * 2017-03-20 2018-10-09 徐寒梅 一种融合蛋白及其制备方法和其在制备治疗眼科疾病、抗炎、抗肿瘤药物中的应用
WO2019052405A1 (zh) * 2017-09-14 2019-03-21 南京安吉生物科技有限公司 马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用
WO2019109819A1 (zh) 2017-12-06 2019-06-13 天士力生物医药股份有限公司 一种hm-3融合蛋白及其应用
CN111855876A (zh) * 2020-07-10 2020-10-30 北京赛升药业股份有限公司 一种安替安吉肽有关物质的检测方法
CN114230676A (zh) * 2021-12-22 2022-03-25 天士力生物医药股份有限公司 重组hm-3融合蛋白及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113488512A (zh) * 2021-06-23 2021-10-08 深圳市华星光电半导体显示技术有限公司 显示面板及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1699408A (zh) * 2005-06-03 2005-11-23 中国药科大学 高效抑制血管生成多肽及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
HRP20050585A2 (en) * 2002-11-25 2006-02-28 Attenuon Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof
KR100863060B1 (ko) * 2006-06-02 2008-10-10 베이징 선바이오 바이오테크, 코오퍼레이션, 리미티드 암 억제 활동을 하는 재조합 단백질, 그 암호화 유전자 및 재조합 단백질을 활성성분으로 포함하는 암치료용 약학적 조성물
CN102145161A (zh) * 2011-04-07 2011-08-10 中国药科大学 整合素阻断剂在制备治疗肿瘤药物中的应用
CN102178656B (zh) * 2011-05-12 2012-08-22 内蒙古奇特生物高科技（集团）有限公司 Hm-3多肽冻干粉制剂及其制备方法
CN102205110B (zh) * 2011-05-18 2014-03-26 中国药科大学 整合素阻断剂在制备治疗新生血管性眼病药物中的应用
CN102417540A (zh) * 2011-11-21 2012-04-18 中国药科大学 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
CN104127378A (zh) * 2014-08-11 2014-11-05 中国药科大学 mPEG-SC20K-HM-3多肽注射液及其制备方法和用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1699408A (zh) * 2005-06-03 2005-11-23 中国药科大学 高效抑制血管生成多肽及其制备方法和应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
《International Journal of Molecular Sciences》 20110419 Zhendong Liu "In Vivo Anti-Tumor Activity of Polypeptide HM-3 Modified by Different Polyethylene Glycols (PEG)" 摘要 1-3 , 第12期 *
《J. Biochem.》 20100629 Beili Zhu "Site-specific modification of anti-angiogenesis peptide HM-3 by polyethylene glycol molecular weight of 20 kDa" 摘要，344页左栏首段 1-3 第148卷, 第3期 *
BEILI ZHU: ""Site-specific modification of anti-angiogenesis peptide HM-3 by polyethylene glycol molecular weight of 20 kDa"", 《J. BIOCHEM.》, vol. 148, no. 3, 29 June 2010 (2010-06-29), pages 344 *
ZHENDONG LIU: ""In Vivo Anti-Tumor Activity of Polypeptide HM-3 Modified by Different Polyethylene Glycols (PEG)"", 《INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES》, no. 12, 19 April 2011 (2011-04-19) *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075600A1 (zh) * 2011-11-21 2013-05-30 Xu Hanmei 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
CN103623394A (zh) * 2013-12-11 2014-03-12 南京安吉生物科技有限公司 一种peg-hm-3和铂类、紫杉醇类或他滨类药物在制备实体瘤药物中的用途
CN103656615A (zh) * 2013-12-11 2014-03-26 南京安吉生物科技有限公司 一种hm-3和铂类、紫杉醇类或他滨类药物在制备实体瘤药物中的用途
CN103656615B (zh) * 2013-12-11 2017-01-04 南京安吉生物科技有限公司 一种hm-3和铂类、紫杉醇类或他滨类药物在制备实体瘤药物中的用途
CN103739669B (zh) * 2013-12-31 2015-08-26 浙江元太生物科技有限公司 一种抑制白介素-6多肽及其应用
CN103739673A (zh) * 2013-12-31 2014-04-23 罗瑞雪 一种聚乙二醇修饰的抑制白介素-6多肽及其应用
CN103739671A (zh) * 2013-12-31 2014-04-23 罗瑞雪 一种聚乙二醇修饰的抑制核因子－κB多肽及其应用
CN103739669A (zh) * 2013-12-31 2014-04-23 罗瑞雪 一种抑制白介素-6多肽及其应用
CN103736078A (zh) * 2014-01-09 2014-04-23 南京安吉生物科技有限公司 mPEG-HM-3多肽冻干粉针制剂及其制备方法和用途
CN103720667A (zh) * 2014-01-09 2014-04-16 中国药科大学 Ap-25多肽冻干粉针制剂及其制备方法和用途
CN103720667B (zh) * 2014-01-09 2016-04-13 中国药科大学 Ap-25多肽冻干粉针制剂及其制备方法和用途
CN103819542A (zh) * 2014-02-28 2014-05-28 中国药科大学 一种聚乙二醇修饰及蛋白质融合表达的整合素阻断剂ap-25及其应用
CN104127378A (zh) * 2014-08-11 2014-11-05 中国药科大学 mPEG-SC20K-HM-3多肽注射液及其制备方法和用途
CN105622721A (zh) * 2015-12-16 2016-06-01 李斯文 一种聚乙二醇修饰的血管生成抑制剂hs-1及其应用
WO2017173905A1 (zh) * 2016-04-06 2017-10-12 南京安吉生物科技有限公司 聚乙二醇修饰的血管生成抑制剂hm-1及其应用
US10869931B2 (en) 2016-04-06 2020-12-22 Nanjing Anji Biological Technology Co., Ltd Polyethylene glycol-modified angiogenesis inhibitor HM-1 and application thereof
CN105646667A (zh) * 2016-04-06 2016-06-08 南京安吉生物科技有限公司 聚乙二醇修饰的血管生成抑制剂hm-1及其应用
CN108623693A (zh) * 2017-03-20 2018-10-09 徐寒梅 一种融合蛋白及其制备方法和其在制备治疗眼科疾病、抗炎、抗肿瘤药物中的应用
CN108623693B (zh) * 2017-03-20 2022-03-25 徐寒梅 一种融合蛋白及其制备方法和其在制备治疗眼科疾病、抗炎、抗肿瘤药物中的应用
WO2019052405A1 (zh) * 2017-09-14 2019-03-21 南京安吉生物科技有限公司 马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用
CN107857800A (zh) * 2017-11-09 2018-03-30 北京赛升药业股份有限公司 一种长效整合素抑制剂及其应用
CN107857800B (zh) * 2017-11-09 2020-05-05 北京赛升药业股份有限公司 一种长效整合素抑制剂及其应用
WO2019109819A1 (zh) 2017-12-06 2019-06-13 天士力生物医药股份有限公司 一种hm-3融合蛋白及其应用
CN109879969A (zh) * 2017-12-06 2019-06-14 天士力生物医药股份有限公司 一种hm-3融合蛋白及其应用
US11655308B2 (en) 2017-12-06 2023-05-23 Tasly Biopharmaceuticals Co., Ltd. HM-3 fusion protein and application thereof
CN109879969B (zh) * 2017-12-06 2024-04-09 天士力生物医药股份有限公司 一种hm-3融合蛋白及其应用
TWI910095B (zh) * 2017-12-06 2026-01-01 大陸商天士力醫藥集團股份有限公司 一種hm-3融合蛋白質及其應用
CN111855876A (zh) * 2020-07-10 2020-10-30 北京赛升药业股份有限公司 一种安替安吉肽有关物质的检测方法
CN111855876B (zh) * 2020-07-10 2023-05-02 北京赛升药业股份有限公司 一种安替安吉肽有关物质的检测方法
CN114230676A (zh) * 2021-12-22 2022-03-25 天士力生物医药股份有限公司 重组hm-3融合蛋白及其应用
CN114230676B (zh) * 2021-12-22 2024-06-11 天士力生物医药股份有限公司 重组hm-3融合蛋白及其应用

Also Published As

Publication number Publication date
EP2784093B1 (en) 2019-10-09
EP2784093A4 (en) 2015-08-05
EP2784093A1 (en) 2014-10-01
US20170100489A1 (en) 2017-04-13
US20140329759A1 (en) 2014-11-06
WO2013075600A1 (zh) 2013-05-30
AU2012343020B2 (en) 2016-05-19
KR20140096373A (ko) 2014-08-05
IN2014CN04482A (https=) 2015-09-04
KR20190090872A (ko) 2019-08-02
KR102106485B1 (ko) 2020-05-04
AU2012343020A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
CN102417540A (zh) 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
Ying et al. A stabilized peptide ligand for multifunctional glioma targeted drug delivery
AU2017234460B2 (en) Multi-functional fusion polypeptide, preparation method thereof, and application of same
He et al. Turing milk into pro-apoptotic oral nanotherapeutic: De novo bionic chiral-peptide supramolecule for cancer targeted and immunological therapy
Yin et al. Tumor targeting and microenvironment-responsive multifunctional fusion protein for pro-apoptotic peptide delivery
US20220152146A1 (en) Cyclic prosaposin peptides and uses thereof
AU2012361902A1 (en) Integrin blocker polypeptide and use thereof
CN111995686B (zh) 一种具有抗血管生成活性的药物及其制备方法
CN105315350A (zh) 抗肿瘤血管生成多肽mPEG-Mal-Cys-AS16
CN104910280A (zh) 一种融合多肽及其在制备抗肿瘤药物中的应用
CN105085633B (zh) 具有缓激肽受体结合活性的多肽及其用途
Yu et al. Hydrocarbon stapling modification of peptide alyteserin‐2a: discovery of novel stapled peptide antitumor agents
CN102372770A (zh) 一种抑血管生成素、纯化方法及含有它们的药物组合物
Qian Current status and trends in research and development of polypeptide drugs
CN108640973A (zh) 一种靶向作用Syntenin蛋白的多肽及其二聚体和应用
CN105622721A (zh) 一种聚乙二醇修饰的血管生成抑制剂hs-1及其应用
CN1883710B (zh) 抗肿瘤寡肽的化学修饰方法及其制药用途
CN103172745A (zh) 包含免疫球蛋白Fc片段的长效人内皮抑素
CN106519007B (zh) 一种单链多肽及其在制备用于预防和治疗胃癌的药物中的应用
CN108640974A (zh) 一种靶向作用Syntenin蛋白PDZ结构域的多肽及其二聚体
CN107857800B (zh) 一种长效整合素抑制剂及其应用
US11771736B2 (en) Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same
CN103819542A (zh) 一种聚乙二醇修饰及蛋白质融合表达的整合素阻断剂ap-25及其应用
WO2024223883A1 (en) Peptides for cancer therapy
CN102827269B (zh) 胸腺肽α1的类似物及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120418